HBT
ALXN

Hills Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Hills Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,273
Closed -$785K – 262
2021
Q2 		$785K Sell
4,273
-670
-14% -$115K 0.12% 114
2021
Q1 		$756K Sell
4,943
-7,332
-60% -$1.13M 0.12% 111
2020
Q4 		$1.92M Buy
12,275
+36
+0.3% +$4.63K 0.34% 69
2020
Q3 		$1.4M Buy
12,239
+1,004
+9% +$108K 0.27% 77
2020
Q2 		$1.26M Sell
11,235
-2,658
-19% -$282K 0.27% 78
2020
Q1 		$1.25M Buy
13,893
+876
+7% +$86K 0.37% 61
2019
Q4 		$1.41M Buy
13,017
+143
+1% +$15.3K 0.33% 67
2019
Q3 		$1.26M Buy
12,874
+3,313
+35% +$373K 0.32% 67
2019
Q2 		$1.25M Buy
9,561
+266
+3% +$34.3K 0.32% 68
2019
Q1 		$1.26M Buy
9,295
+1,120
+14% +$139K 0.34% 65
2018
Q4 		$796K Buy
8,175
+431
+6% +$50.9K 0.25% 79
2018
Q3 		$1.08M Buy
7,744
+456
+6% +$57.2K 0.29% 73
2018
Q2 		$905K Buy
7,288
+1,100
+18% +$129K 0.26% 71
2018
Q1 		$690K Buy
6,188
+1,025
+20% +$123K 0.21% 80
2017
Q4 		$617K Buy
5,163
+1,228
+31% +$150K 0.18% 90
2017
Q3 		$552K Buy
3,935
+637
+19% +$86.5K 0.17% 91
2017
Q2 		$401K Buy
+3,298
New +$384K 0.13% 98

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Hills Bank & Trust's ALXN Position: Q3 2021 in Review

Hills Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,273 shares — an estimated $785K sold.

Hills Bank & Trust first reported a position in ALXN in Q2 2017 and held it in 17 quarters. The position peaked at $1.92M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Hills Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Hills Bank & Trust sold 4,273 Alexion Pharmaceuticals shares in Q3 2021, an estimated $785K.
  • Hills Bank & Trust first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 17 quarters.
  • Hills Bank & Trust's Alexion Pharmaceuticals position peaked at $1.92M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Hills Bank & Trust's 13F filing for Q3 2021, filed 27 Oct 2021.